KR20190005858A - 어레이 방법 및 그의 용도 - Google Patents

어레이 방법 및 그의 용도 Download PDF

Info

Publication number
KR20190005858A
KR20190005858A KR1020187032184A KR20187032184A KR20190005858A KR 20190005858 A KR20190005858 A KR 20190005858A KR 1020187032184 A KR1020187032184 A KR 1020187032184A KR 20187032184 A KR20187032184 A KR 20187032184A KR 20190005858 A KR20190005858 A KR 20190005858A
Authority
KR
South Korea
Prior art keywords
ser
gly
leu
ala
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020187032184A
Other languages
English (en)
Korean (ko)
Inventor
칼 보레바에크
안나 산스트룀 예르드트손
크리스테르 빈그렌
Original Assignee
이뮤노비아 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이뮤노비아 에이비 filed Critical 이뮤노비아 에이비
Publication of KR20190005858A publication Critical patent/KR20190005858A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • G01N33/57438—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/5436—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand physically entrapped within the solid phase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G01N33/57484—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Gastroenterology & Hepatology (AREA)
KR1020187032184A 2016-05-10 2017-05-10 어레이 방법 및 그의 용도 Abandoned KR20190005858A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1608192.9A GB201608192D0 (en) 2016-05-10 2016-05-10 Method, array and use thereof
GB1608192.9 2016-05-10
PCT/EP2017/061202 WO2017194613A2 (en) 2016-05-10 2017-05-10 Method, array and use thereof

Publications (1)

Publication Number Publication Date
KR20190005858A true KR20190005858A (ko) 2019-01-16

Family

ID=56297465

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187032184A Abandoned KR20190005858A (ko) 2016-05-10 2017-05-10 어레이 방법 및 그의 용도

Country Status (13)

Country Link
US (2) US20200011872A1 (https=)
EP (2) EP3907509A3 (https=)
JP (2) JP2019516981A (https=)
KR (1) KR20190005858A (https=)
CN (1) CN109564221A (https=)
AU (1) AU2017261762A1 (https=)
BR (1) BR112018073178A2 (https=)
CA (1) CA3022022A1 (https=)
GB (1) GB201608192D0 (https=)
IL (1) IL262824A (https=)
MX (1) MX2018013621A (https=)
RU (1) RU2018138639A (https=)
WO (1) WO2017194613A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008117067A2 (en) * 2007-03-27 2008-10-02 Carl Arne Krister Borrebaeck Protein signature/markers for the detection of adenocarcinoma
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
EP4247434A4 (en) * 2020-11-18 2024-10-23 Pandion Operations, Inc. THERAPEUTIC AGENTS TARGETING MADCAM AND THEIR USES
CA3202255A1 (en) 2020-12-21 2022-06-30 Hayley WARSINSKE Markers for the early detection of colon cell proliferative disorders
WO2022204332A1 (en) * 2021-03-24 2022-09-29 Combangio, Inc. Compositions comprising c-met agonist antibodies and methods for use in ocular treatment
CN117305244B (zh) * 2023-03-28 2025-02-28 湖南省肿瘤医院 人胰腺癌细胞株及其应用
CN120177800B (zh) * 2025-05-23 2025-10-10 四川大学 血液生物标志物cfp在制备急性胰腺炎诊断试剂的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE12586T1 (de) 1980-05-02 1985-04-15 Edward P Davis Beinentlastungsgeraet.
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5856090A (en) 1994-09-09 1999-01-05 The Scripps Research Institute DNA-methylase linking reaction
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
DE60325541D1 (de) * 2002-10-31 2009-02-12 Hoffmann La Roche Verfahren/Präparat zur Erkennung von Pankreaskrebs
US9005613B2 (en) * 2003-06-16 2015-04-14 Immunomedics, Inc. Anti-mucin antibodies for early detection and treatment of pancreatic cancer
JP2009505632A (ja) * 2005-07-27 2009-02-12 オンコセラピー・サイエンス株式会社 膵臓癌関連遺伝子であるｃｓｔ６およびｇａｂｒｐ
WO2008117067A2 (en) * 2007-03-27 2008-10-02 Carl Arne Krister Borrebaeck Protein signature/markers for the detection of adenocarcinoma
CN103415624B (zh) * 2010-08-13 2017-03-01 私募蛋白质体公司 胰腺癌生物标记及其用途
GB201103726D0 (en) * 2011-03-04 2011-04-20 Immunovia Ab Method, array and use thereof
WO2013052480A1 (en) * 2011-10-03 2013-04-11 The Board Of Regents Of The University Of Texas System Marker-based prognostic risk score in colon cancer
WO2013106844A2 (en) * 2012-01-13 2013-07-18 Oncocyte Corporation Methods and compositions for the treatment and diaginosis of pancreatic cancer
KR20140094180A (ko) * 2013-01-21 2014-07-30 연세대학교 산학협력단 보체인자 b 단백질에 특이적으로 결합하는 폴리펩타이드 또는 항체를 포함하는 췌장암 진단용 조성물
EP2972375A2 (en) * 2013-03-13 2016-01-20 Creatics LLC Methods and compositions for detecting pancreatic cancer
CN105102637B (zh) * 2013-04-17 2018-05-22 Lg电子株式会社 提取胰腺癌诊断生物标志物的方法、用于该方法的计算装置、胰腺癌诊断生物标志物以及包含该生物标志物的胰腺癌诊断装置
RU2693006C2 (ru) * 2013-10-01 2019-07-01 Торэй Индастриз, Инк. Способ выявления опухоли поджелудочной железы, антитела и набор для выявления опухоли поджелудочной железы
GB201319878D0 (en) * 2013-11-11 2013-12-25 Immunovia Ab Method, Array and use thereof
US10451628B2 (en) * 2014-05-07 2019-10-22 University Of Utah Research Foundation Biomarkers and methods for diagnosis of early stage pancreatic ductal adenocarcinoma
KR20150129932A (ko) * 2014-05-12 2015-11-23 연세대학교 산학협력단 보체인자 b 단백질에 특이적으로 결합하는 항체를 포함하는 췌장암 진단용 키트
CN105092845A (zh) * 2015-07-10 2015-11-25 深圳市贝沃德克生物技术研究院有限公司 胰腺癌蛋白生物标记物、用途及其检测芯片和检测装置
GB201516801D0 (en) * 2015-09-22 2015-11-04 Immunovia Ab Method, array and use thereof

Non-Patent Citations (53)

* Cited by examiner, † Cited by third party
Title
Alonzo, T.A., Pepe, M.S., Moskowitz, C.S., 2002. Sample size calculations for comparative studies of medical tests for detecting presence of disease. Stat Med. 21, 835-852.
Bauden, M., Pamart, D., Ansari, D., Herzog, M., Eccleston, M., Micallef, J., Andersson, B., Andersson, R., 2015. Circulating nucleosomes as epigenetic biomarkers in pancreatic cancer. Clin Epigenet 7, 106.
Bellone, G., Smirne, C., Mauri, F.A., Tonel, E., Carbone, A., Buffolino, A., Dughera, L., Robecchi, A., Pirisi, M., Emanuelli, G., 2006. Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival. Cancer Immunol Immunother. 55, 684-698.
Brand, R.E., Nolen, B.M., Zeh, H.J., Allen, P.J., Eloubeidi, M.A., Goldberg, M., Elton, E., Arnoletti, J.P., Christein, J.D., Vickers, S.M., Langmead, C.J., Landsittel, D.P., Whitcomb, D.C., Grizzle, W.E., Lokshin, A.E., 2011. Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res. 17, 805-816.
Bunger, S., Laubert, T., Roblick, U.J., Habermann, J.K., 2011. Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview. J Cancer Res Clin Oncol. 137, 375-389.
Carlsson, A., Wingren, C., Ingvarsson, J., Ellmark, P., Baldertorp, B., Ferno, M., Olsson, H., Borrebaeck, C.A., 2008. Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays. Eur J Cancer 44, 472-480.
Carlsson, A., Wingren, C., Kristensson, M., Rose, C., Ferno, M., Olsson, H., Jernstrom, H., Ek, S., Gustavsson, E., Ingvar, C., Ohlsson, M., Peterson, C., Borrebaeck, C.A., 2011a. Molecular serum portraits in patients with primary breast cancer predict the development of distant metastases. Proc Natl Acad Sci U. S. A. 108, 14252-14257.
Carlsson, A., Wuttge, D.M., Ingvarsson, J., Bengtsson, A.A., Sturfelt, G., Borrebaeck, C.A., Wingren, C., 2011b. Serum protein profiling of systemic lupus erythematosus and systemic sclerosis using recombinant antibody microarrays. Mol Cell Proteomics. 10, M110 005033.
Chen, J., Wu, W., Zhen, C., Zhou, H., Yang, R., Chen, L., Hu, L., 2013. Expression and clinical significance of complement C3, complement C4b1 and apolipoprotein E in pancreatic cancer. Oncol Lett. 6, 43-48.
Conlon, K.C., Klimstra, D.S., Brennan, M.F., 1996. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg. 223, 273-279.
Coussens, L.M., Werb, Z., 2002. Inflammation and cancer. Nature 420, 860-867.
Eyigor, C., Karaca, B., Kuzeyli-Yildirim, Y., Uslu, R., Uyar, M., Coker, A., 2010. Does the tumor localization in advanced pancreatic cancer have an influence on the management of symptoms and pain. J B.U.ON. 15, 543-546.
Feldmann, G., Mishra, A., Bisht, S., Karikari, C., Garrido-Laguna, I., Rasheed, Z., Ottenhof, N.A., Dadon, T., Alvarez, H., Fendrich, V., Rajeshkumar, N.V., Matsui, W., Brossart, P., Hidalgo, M., Bannerji, R., Maitra, A., Nelkin, B.D., 2011. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther. 12, 598-609.
Furukawa, H., Okada, S., Saisho, H., Ariyama, J., Karasawa, E., Nakaizumi, A., Nakazawa, S., Murakami, K., Kakizoe, T., 1996. Clinicopathologic features of small pancreatic adenocarcinoma. A collective study. Cancer 78, 986-990.
Gabitass, R.F., Annels, N.E., Stocken, D.D., Pandha, H.A., Middleton, G.W., 2011. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother. 60, 1419-1430.
Gangi, S., Fletcher, J.G., Nathan, M.A., Christensen, J.A., Harmsen, W.S., Crownhart, B.S., Chari, S.T., 2004. Time interval between abnormalities seen on CT and the clinical diagnosis of pancreatic cancer: retrospective review of CT scans obtained before diagnosis. Am J Roentgenol. 182, 897-903.
Gerdtsson, A.S.M., N.; Sall, A.; Real, F. X.; Porta, M.; Skoog, P.; Persson, H.; Wingren, C.; Borrebaeck, C. A. K 2015 A Multicenter Trial Defining a Serum Protein Signature Associated with Pancreatic Ductal Adenocarcinoma. Int J Proteomics 2015.
Gupta, S., Venkatesh, A., Ray, S., Srivastava, S., 2014. Challenges and prospects for biomarker research: a current perspective from the developing world. Biochim Biophys Acta 1844, 899-908.
Haab, B.B., Geierstanger, B.H., Michailidis, G., Vitzthum, F., Forrester, S., Okon, R., Saviranta, P., Brinker, A., Sorette, M., Perlee, L., Suresh, S., Drwal, G., Adkins, J.N., Omenn, G.S., 2005. Immunoassay and antibody microarray analysis of the HUPO Plasma Proteome Project reference specimens: systematic variation between sample types and calibration of mass spectrometry data. Proteomics 5, 3278-3291.
Honda, K., Okusaka, T., Felix, K., Nakamori, S., Sata, N., Nagai, H., Ioka, T., Tsuchida, A., Shimahara, T., Shimahara, M., Yasunami, Y., Kuwabara, H., Sakuma, T., Otsuka, Y., Ota, N., Shitashige, M., Kosuge, T., Buchler, M.W., Yamada, T., 2012. Altered plasma apolipoprotein modifications in patients with pancreatic cancer: protein characterization and multi-institutional validation. PLoS One 7, e46908.
Hou, J., Xu, J., Jiang, R., Wang, Y., Chen, C., Deng, L., Huang, X., Wang, X., Sun, B., 2013. Estrogen-sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3. Hepatol. 57, 678-688.
Huang, Y.T., Li, F.F., Ke, C., Li, Z., Li, Z.T., Zou, X.F., Zheng, X.X., Chen, Y.P., Zhang, H., 2013. PTPRO promoter methylation is predictive of poorer outcome for HER2-positive breast cancer: indication for personalized therapy. J Transl Med. 11, 245.
Ingvarsson, J., Wingren, C., Carlsson, A., Ellmark, P., Wahren, B., Engstrom, G., Harmenberg, U., Krogh, M., Peterson, C., Borrebaeck, C.A., 2008. Detection of pancreatic cancer using antibody microarray-based serum protein profiling. Proteomics 8, 2211-2219.
Itakura, J., Ishiwata, T., Friess, H., Fujii, H., Matsumoto, Y., Buchler, M.W., Korc, M., 1997. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res. 3, 1309-1316.
Jimenez-Vidal, M., Srivastava, J., Putney, L.K., Barber, D.L., 2010. Nuclear-localized calcineurin homologous protein CHP1 interacts with upstream binding factor and inhibits ribosomal RNA synthesis. J Biol Chem. 285, 36260-36266.
Jin, Q., Kong, B., Yang, X., Cui, B., Wei, Y., Yang, Q., 2007. Overexpression of CHP2 enhances tumor cell growth, invasion and metastasis in ovarian cancer. In vivo 21, 593-598.
Johnson, W.E., Li, C., Rabinovic, A., 2007. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8, 118-127.
Lau, M.K., Davila, J.A., Shaib, Y.H., 2010. Incidence and survival of pancreatic head and body and tail cancers: a population-based study in the United States. Pancreas 39, 458-462.
Ling, Q., Xu, X., Zheng, S.S., Kalthoff, H., 2013. The diversity between pancreatic head and body/tail cancers: clinical parameters and in vitro models. Hepatobil Pancreat Dis Intl. 12, 480-487.
Locker, G.Y., Hamilton, S., Harris, J., Jessup, J.M., Kemeny, N., Macdonald, J.S., Somerfield, M.R., Hayes, D.F., Bast, R.C., Jr., 2006. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 24, 5313-5327.
Melo, S.A., Luecke, L.B., Kahlert, C., Fernandez, A.F., Gammon, S.T., Kaye, J., LeBleu, V.S., Mittendorf, E.A., Weitz, J., Rahbari, N., Reissfelder, C., Pilarsky, C., Fraga, M.F., Piwnica-Worms, D., Kalluri, R., 2015. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 523, 177-182.
Motiwala, T., Kutay, H., Ghoshal, K., Bai, S., Seimiya, H., Tsuruo, T., Suster, S., Morrison, C., Jacob, S.T., 2004. Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer. Proc Natl Acad Sci U. S. A. 101, 13844-13849.
Pannala, R., Basu, A., Petersen, G.M., Chari, S.T., 2009. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 10, 88-95.
Pauly, F., Smedby, K.E., Jerkeman, M., Hjalgrim, H., Ohlsson, M., Rosenquist, R., Borrebaeck, C.A., Wingren, C., 2014. Identification of B-cell lymphoma subsets by plasma protein profiling using recombinant antibody microarrays. Leukemia Res. 38, 682-690.
Pelaez-Luna, M., Takahashi, N., Fletcher, J.G., Chari, S.T., 2007. Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis. Am J Gastroenterol. 102, 2157-2163.
Rastogi, T., Hildesheim, A., Sinha, R., 2004. Opportunities for cancer epidemiology in developing countries. Nature Rev Cancer 4, 909-917.
Sandstrom, A., Andersson, R., Segersvard, R., Lohr, M., Borrebaeck, C.A., Wingren, C., 2012. Serum proteome profiling of pancreatitis using recombinant antibody microarrays reveals disease-associated biomarker signatures. Proteomics Clin Appl. 6, 486-496.
Shaw, V.E., Lane, B., Jenkinson, C., Cox, T., Greenhalf, W., Halloran, C.M., Tang, J., Sutton, R., Neoptolemos, J.P., Costello, E., 2014. Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease. Mol Cancer 13, 114.
Shimizu, Y., Yasui, K., Matsueda, K., Yanagisawa, A., Yamao, K., 2005. Small carcinoma of the pancreas is curable: new computed tomography finding, pathological study and postoperative results from a single institute. J Gastroenterol Hepatol. 20, 1591-1594.
Sohn, T.A., Yeo, C.J., Cameron, J.L., Koniaris, L., Kaushal, S., Abrams, R.A., Sauter, P.K., Coleman, J., Hruban, R.H., Lillemoe, K.D., 2000. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 567-579.
Song, M.S., Salmena, L., Carracedo, A., Egia, A., Lo-Coco, F., Teruya-Feldstein, J., Pandolfi, P.P., 2008. The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature 455, 813-817.
Steinhauer, C., Wingren, C., Hager, A.C., Borrebaeck, C.A., 2002. Single framework recombinant antibody fragments designed for protein chip applications. BioTechniques Suppl. 38-45.
Stoevesandt, O., Taussig, M.J., 2012. European and international collaboration in affinity proteomics. N biotechnol. 29, 511-514.
Surinova, S., Schiess, R., Huttenhain, R., Cerciello, F., Wollscheid, B., Aebersold, R., 2011. On the development of plasma protein biomarkers. J Proteome Res. 10, 5-16.
Watanabe, I., Sasaki, S., Konishi, M., Nakagohri, T., Inoue, K., Oda, T., Kinoshita, T., 2004. Onset symptoms and tumor locations as prognostic factors of pancreatic cancer. Pancreas 28, 160-165.
Wingren, C., Borrebaeck, C.A., 2008. Antibody microarray analysis of directly labelled complex proteomes. Curr Opin Biotechnol. 19, 55-61.
Wingren, C., Sandstrom, A., Segersvard, R., Carlsson, A., Andersson, R., Lohr, M., Borrebaeck, C.A., 2012. Identification of serum biomarker signatures associated with pancreatic cancer. Cancer Res. 72, 2481-2490.
Wingren, C., Steinhauer, C., Ingvarsson, J., Persson, E., Larsson, K., Borrebaeck, C.A., 2005. Microarrays based on affinity-tagged single-chain Fv antibodies: sensitive detection of analyte in complex proteomes. Proteomics 5, 1281-1291.
Winter, J.M., Tang, L.H., Klimstra, D.S., Brennan, M.F., Brody, J.R., Rocha, F.G., Jia, X., Qin, L.X., D'Angelica, M.I., DeMatteo, R.P., Fong, Y., Jarnagin, W.R., O'Reilly, E.M., Allen, P.J., 2012. A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. PLoS One 7, e40157.
Wu, T.C., Shao, Y.F., Shan, Y., Wu, J.X., Zhao, P., 2007. [Surgical effect of malignant tumor of body and tail of the pancreas: compare with pancreatic head cancer]. Zhonghua wai ke za zhi [Chinese journal of surgery] 45, 30-33.
Xia, C., Ma, W., Stafford, L.J., Liu, C., Gong, L., Martin, J.F., Liu, M., 2003. GGAPs, a new family of bifunctional GTP-binding and GTPase-activating proteins. Mol Cell Biol. 23, 2476-2488.
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R.H., Eshleman, J.R., Nowak, M.A., Velculescu, V.E., Kinzler, K.W., Vogelstein, B., Iacobuzio-Donahue, C.A., 2010. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114-1117.
Zhao, G.Y., Lin, Z.W., Lu, C.L., Gu, J., Yuan, Y.F., Xu, F.K., Liu, R.H., Ge, D., Ding, J.Y., 2014. USP7 overexpression predicts a poor prognosis in lung squamous cell carcinoma and large cell carcinoma. Tumour Biol. 36, 1721-1729.

Also Published As

Publication number Publication date
US20200011872A1 (en) 2020-01-09
EP3455632A2 (en) 2019-03-20
US20220206004A1 (en) 2022-06-30
MX2018013621A (es) 2019-04-25
EP3907509A2 (en) 2021-11-10
RU2018138639A3 (https=) 2020-10-30
IL262824A (en) 2018-12-31
AU2017261762A1 (en) 2018-11-15
JP2019516981A (ja) 2019-06-20
CN109564221A (zh) 2019-04-02
BR112018073178A2 (pt) 2019-02-19
GB201608192D0 (en) 2016-06-22
WO2017194613A2 (en) 2017-11-16
JP2021165745A (ja) 2021-10-14
RU2018138639A (ru) 2020-06-10
EP3907509A3 (en) 2021-12-29
CA3022022A1 (en) 2017-11-16
WO2017194613A3 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
KR20190005858A (ko) 어레이 방법 및 그의 용도
EP3353552B1 (en) Method and array for diagnosing pancreatic cancer in an individual
KR102240473B1 (ko) 방법, 어레이 및 그의 용도
KR102014890B1 (ko) 췌장암의 존재를 결정하기 위한 방법, 어레이 및 그의 용도
KR20190109422A (ko) 방법, 어레이 및 그 용도
JP5422785B2 (ja) 質量分析法を利用した複数癌腫の血液検出のための方法および生物マーカー
WO2015189591A2 (en) Methods and arrays for use in the same
KR20150137118A (ko) 전립선암의 바이오마커 검출에서 사용하기 위한 방법 및 어레이
JP6361943B2 (ja) 補体因子ｂタンパク質に特異的に結合する抗体及び糖鎖抗原１９−９タンパク質に特異的に結合する抗体を含む膵臓癌診断用キット
US20140248297A1 (en) Predictors of response to immunotherapy
CN110554196A (zh) 胰腺癌预后标志物及其应用
Akçay Development and validation of methods for the diagnosis of lung cancer via serological biomarkers

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

PC1904 Unpaid initial registration fee

St.27 status event code: A-2-2-U10-U14-oth-PC1904

St.27 status event code: N-2-6-B10-B12-nap-PC1904

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000